超出DHFR放大范围的人类癌症细胞系中对甲醇抗的动态基因组变化表明,预防耐药性的潜在新目标是预防耐药性
Xiang-Ning Meng1,2, Jin-Fa Ma1,2, Yang-He Liu1,2
1Key laboratory of preservation of human genetic resources and disease control in China (Harbin Medical University), Ministry of Education, Harbin, 150081, China.
癌症中甲甲酸耐药性通过DHFR基因放大在不同的阶段发展. 染色体外DNA (ecDNA) 的形成是关键的驱动因素,FAM151B,MSH3和ZFYVE16也影响了耐药性.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 基因放大二叶酸减少酶 (DHFR) 是癌症中甲状腺酸盐 (MTX) 耐药性的已知机制.
- 对于MTX耐药性的早期阶段和详细进展仍然不完全理解.
研究的目的:
- 阐明结肠癌细胞中MTX抵抗的进化轨迹.
- 确定驱动抗药性发展的关键遗传和蛋白质基因变化.
- 为了发现潜在的新目标来克服MTX阻力.
主要方法:
- 进行了基因组,转录和蛋白质组分析.
- 人类结肠癌细胞经历了连续增加的MTX水平.
- 在不同阻力阶段进行了对比分析.
主要成果:
- MTX耐药性通过三个基因组放大阶段进化:预放大,同质染色区域 (HSR) 和异染色体DNA (ecDNA).
- 证实DHFR放大和表达增加是主要的驱动因素,但DHFR在早期抵抗阶段并不关键.
- 在ecDNA阶段FAM151B蛋白增加可能会降低MTX灵敏度,而MSH3和ZFYVE16尽管蛋白质表达发生了改变,但仍起作用.
结论:
- 该研究详细介绍了MTX耐药性的进化路径,强调了ecDNAs作为重要的目标.
- FAM151B,MSH3和ZFYVE16被确定为在耐药性的后期阶段潜在的重要因素.
- 这些发现为预防或克服癌症抗药性提供了洞察力,并为研究其他抗药性机制提供了一个模型.
更多相关视频
09:58Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mismatch Repair
